Johnson & Johnson (NYSE: JNJ) reported its fiscal third-quarter financial results before the markets opened on Tuesday. The company said that it had $1.90 in earnings per share (EPS) and $19.7 billion in revenue, which compares with consensus estimates from Thomson Reuters of $1.80 in EPS and revenue of $19.28 billion. In the same period of last year, it posted EPS of $1.68 and $17.82 billion in revenue.

Domestic sales increased 9.7%. International sales increased 10.9%, reflecting operational growth of 9.3% and a positive currency impact of 1.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide, domestic and international sales each increased 3.8%.

In terms of its segments, the company reported:

• Worldwide Consumer revenues of $3.4 billion increased 2.9% over the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%.
• Worldwide Pharmaceutical revenues of $9.7 billion represented an increase of 15.4% from the prior year, with an operational increase of 14.6% and a positive impact from currency of 0.8%.
• Worldwide Medical Devices revenues of $6.6 billion increased by 7.1% compared to last year, consisting of an operational increase of 6.6% and a positive currency impact of 0.5%.

As for the full year outlook, Johnson & Johnson increased both its EPS forecast to $7.25 to $7.30 and sales guidance to $76.1 billion to $76.5 billion. The consensus estimates call for $7.18 in EPS and $75.83 billion in revenue.

Alex Gorsky, board chair and CEO, commented:

Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth. Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe.

Shares of Johnson & Johnson traded up 1% early Tuesday at $137.52, with a consensus analyst price target of $138.80 and a 52-week trading range of $109.32 to $137.52.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.